Michael Kauffman - Jan 3, 2022 Form 4 Insider Report for Kezar Life Sciences, Inc. (KZR)

Role
Director
Signature
/s/ Marc Belsky, Attorney-in-Fact
Stock symbol
KZR
Transactions as of
Jan 3, 2022
Transactions value $
-$52,700
Form type
4
Date filed
1/5/2022, 05:51 PM
Previous filing
Nov 18, 2021
Next filing
Feb 9, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KZR Common Stock Options Exercise $29.6K +5K +7.85% $5.91* 68.7K Jan 3, 2022 Direct
transaction KZR Common Stock Sale -$82.3K -5K -7.28% $16.45* 63.7K Jan 3, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KZR Stock Option (Right to Buy) Options Exercise $0 -5K -56.21% $0.00 3.9K Jan 3, 2022 Common Stock 5K $5.91 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.164 to $16.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 Fully vested and exercisable.